This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization
← catalyst calendarNCT07587658 · readout in 711 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →. With Sanofi.
Phase
Phase 4
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
754estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-30 | estimated | When the study began enrolling |
| Primary completion | 2028-07-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-07-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
- Drug: dupilumab — also filed as Dupixent®, REGN668, SAR231893
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFTime to first all-cause event
measured Through day 90
Number of moderate or severe COPD exacerbations
measured Through day 90
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed